Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Nona Biosciences Enters Collaboration Agreement with Dragonfly Therapeutics | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Nona Biosciences Enters Collaboration Agreement with Dragonfly Therapeutics

Aims to discover and develop fully human heavy chain only antibodies for bispecific/multi-specific therapeutic antibody generation.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited committed to providing a total solution from “Idea to IND”, has entered into a collaboration agreement with Dragonfly Therapeutics based on Nona’s proprietary fully human heavy chain only antibody (HCAb) transgenic mice platform to discover and develop fully human heavy chain only antibodies for bispecific/multi-specific therapeutic antibody generation.
 
Through the collaboration, Nona Biosciences will provide Dragonfly Therapeutics with access to the HCAb technologies as well as antibody generation services for the targets designated by Dragonfly Therapeutics. Financial terms were not disclosed.
 
The collaboration follows Nona’s recently announced license and collaboration agreement with Moderna for nucleic acid-based immunotherapies for select oncology targets. 
 
Dr. Jingsong Wang, founder, chairman, and CEO of Harbour BioMed said: “The Dragonfly Therapeutics’ collaboration recognizes the potential of both our proprietary platform and antibody discovery capabilities. We believe that our HCAb technology together with our accumulated extensive experience in innovative biologics drug discovery will help our partners generate differentiated therapeutic molecules benefiting the patient worldwide.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters